Summary of Inogen Conference Call Company Overview - **Company**: Inogen - **Industry**: Medical Technology (MedTech), specifically in respiratory care and sleep therapy Key Points and Arguments Business Stabilization and Growth - Inogen has focused on stabilizing the business and returning to profitable growth over the past two years, achieving a **10% growth** in business and returning to **positive adjusted EBITDA** for the first time since 2021 [2][3] - The company aims to transition from a single product focus to a diversified portfolio, launching new products such as the **Voxi 5** stationary concentrator and **Aurora face masks** for obstructive sleep apnea [3][4] Market Expansion and Overlap - Inogen identifies a **30% overlap** between COPD and sleep apnea patient populations, allowing for strategic expansion into the home respiratory care market [5][6] - The Total Addressable Market (TAM) for Inogen is projected to grow from **$400 million** to **$3 billion** in the U.S. alone, leveraging existing brand relationships and expanding into new therapeutic areas [6] Customer Dynamics and Order Timing - In Q4, there was a shift in customer orders due to capital budget constraints, but demand for portable oxygen concentrators (POC) grew by **20%** in 2025 [11][12] - The company expects continued strong demand in both domestic and international B2B markets, despite some near-term order timing challenges [12] International Market Growth - Inogen has seen **15% growth** in international customers, primarily in European markets, and is expanding into Latin America and Asia Pacific, including potential entry into the Chinese and Japanese markets [14] Product Mix and Sales Channels - The company anticipates growth in the B2B channel, with a focus on portable oxygen therapy, while also introducing new products like the Voxi 5 and Aurora mask to enhance margins [18][21] - Inogen aims to balance its sales strategy between B2B and direct-to-consumer channels, ensuring accessibility for all patients [42] Future Financial Guidance - For 2026, Inogen projects **high single-digit revenue growth** and continued improvement in adjusted EBITDA, driven by new product introductions and operational efficiencies [27][29] - The company is committed to maintaining a disciplined approach to operational expenses and cost management to enhance profitability [25] New Product Development - Inogen plans to introduce at least one new product annually, focusing on high-margin areas and clinical differentiation [72] - The company is exploring opportunities in the COPD space and developing a connected care ecosystem to enhance patient outcomes [73] Simeox and Sleep Therapy Market - The Simeox airway clearance product has a projected **$500 million** TAM, with a focus on obtaining reimbursement through clinical trials [57][58] - Inogen has entered the sleep therapy market with the Aurora mask, targeting a **$2 billion** TAM and leveraging partnerships for product development [62][65] Strategic Positioning - Inogen aims to create a comprehensive ecosystem for respiratory care, enhancing brand loyalty and preference among patients and healthcare providers [30][46] - The company emphasizes the importance of product quality and patient comfort in driving market acceptance and compliance [68][69] Additional Important Insights - Inogen's strategy includes leveraging clinical data to support product efficacy and reimbursement efforts, ensuring a robust foundation for future growth [53][54] - The company is focused on building strong partnerships with healthcare providers to enhance service delivery and patient care [43][46] This summary encapsulates the key insights and strategic directions discussed during the Inogen conference call, highlighting the company's growth trajectory, market opportunities, and product innovations.

Core Viewpoint - Inogen, Inc. will participate in the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026, featuring a virtual fireside chat with CEO Kevin Smith [1] Company Overview - Inogen, Inc. is a leading global medical technology company that specializes in innovative respiratory products for homecare settings [1] - The company develops, manufactures, and markets respiratory therapy devices aimed at patients with chronic respiratory conditions [1] - Inogen collaborates with patients, prescribers, home medical equipment providers, and distributors to enhance the availability of its products [1] Event Details - The virtual fireside chat will take place at 3:00 p.m. Eastern Time on March 17, 2026 [1] - A live audio webcast and archived recording will be accessible through the Inogen Investor Relations website [1] Investor Relations - Inogen utilizes its Investor Relations website to disclose material non-public information and comply with Regulation FD [1]

Financial Performance - The company experienced a net foreign currency gain of $1.3 million for the year ended December 31, 2025, compared to a net foreign currency loss of $0.2 million in 2024 and a gain of $0.2 million in 2023[204]. - The company’s quarterly revenue and results of operations have varied significantly in the past, leading to potential volatility in its stock price[226]. - The company’s projections regarding the oxygen therapy market may be overly optimistic, and if the market opportunities are smaller than expected, revenues could be adversely affected[228]. - An impairment charge of $32.9 million was incurred in the quarter ended September 30, 2023, due to the decline in stock price causing market capitalization to fall below its carrying amount[299]. - The company's stock price has fluctuated significantly, trading as high as $12.91 and as low as $5.70 over the last twelve months[297]. - The company has never paid any cash dividends and does not anticipate paying any in the foreseeable future, focusing instead on retaining earnings for business growth[310]. Regulatory Compliance - The company is subject to various regulatory approvals and certifications, which are critical for maintaining its market position and expanding its business[207]. - The company must obtain and maintain regulatory clearances for its medical devices, and delays or denials in these processes could adversely affect product introductions and sales[240]. - The company is subject to extensive federal and state regulations, and non-compliance could result in severe sanctions and operational changes that adversely affect business[237]. - As a healthcare provider, the company faces strict scrutiny from government agencies regarding compliance with Medicare and Medicaid regulations, which could lead to audits and investigations[238]. - Regulatory changes in healthcare laws may affect permissible activities and reimbursement amounts, potentially having a material adverse effect on the company's operations[239]. - The company must navigate complex fraud and abuse laws, including the Anti-Kickback Statute and the Physician Self-Referral Law, to avoid substantial penalties[270][271]. - Non-compliance with HIPAA and HITECH Act could result in significant penalties, adversely affecting financial condition and operational results[265][268]. - The company is exposed to significant civil monetary penalties (CMPs) if found non-compliant with federal healthcare fraud and abuse laws, which could adversely affect its financial condition and operations[276]. - The implementation of prior authorization rules for DMEPOS under Medicare could negatively affect the company's business and financial condition, particularly for items with an average purchase fee of $1,000 or greater[280]. - The company must also comply with international standards, such as ISO and EU's Medical Device Regulation (MDR), to avoid adverse actions that could harm its reputation and business[256][257]. Operational Risks - The company faces potential supply chain constraints and expense inflation that could impact its operating expenses and the affordability of its products for customers[1]. - The company relies on shipping providers for global product delivery, and disruptions in shipping could adversely affect its financial condition and results of operations[205]. - The company is actively managing risks related to currency exchange rate fluctuations through a hedging program, although it does not completely eliminate the impact of such fluctuations[204]. - The company relies on information technology networks and systems, and any disruptions or cybersecurity incidents could result in significant operational impacts and reputational harm[216]. - The company has insurance coverage for certain liabilities related to cybersecurity risks, but this coverage may be limited and inadequate[217]. - The company may incur additional costs due to new laws and regulations, which could restrict its business operations[225]. - The company may face substantial warranty or product liability claims, which could adversely affect its business and financial condition[212]. - The company has experienced turnover in its senior executives, which could lead to inefficiencies and negatively impact its business strategy[215]. - The company is focused on developing new products and improving existing products to increase their value, with expectations regarding the timing of new product launches and product improvements[1]. - The company expects to continue its market expansion efforts and is assessing growth opportunities in new markets[1]. Legal and Compliance Costs - The company may face significant legal and compliance costs due to the Sarbanes-Oxley Act, which requires annual assessments of internal controls over financial reporting[295]. - The company expects incremental costs from operating as a public company to be between $3.0 million and $5.0 million per year due to compliance with regulations[294]. - The company may incur additional costs if exclusive forum provisions in its bylaws are found unenforceable, impacting operational results[304]. - Provisions in the company's charter documents may delay or prevent changes in management or control, potentially affecting stockholder interests[308]. - The company may face challenges in attracting and retaining qualified board members due to increased compliance costs and regulatory requirements[293]. Intellectual Property and Competitive Risks - The company relies on patents and other intellectual property to protect its products, but the uncertainty of patent positions could harm its competitive advantage and future profitability[281]. - Non-payment or delay in payment of patent fees may result in the loss of important patents, diminishing the company's competitive position[284]. - The company may face substantial costs and reputational harm from intellectual property litigation, which could distract management from other critical business tasks[289]. - The company’s ability to compete may be harmed if unauthorized use or disclosure of trade secrets occurs, despite efforts to protect proprietary information[290].

Core Insights - Inogen, Inc. reported an adjusted loss per share of 15 cents for Q4 2025, which is an improvement from a loss of 24 cents in the same quarter last year and better than the Zacks Consensus Estimate of a loss of 36 cents per share [1][10] - The company’s revenues for the fourth quarter were $81.7 million, reflecting a 2% year-over-year increase, although this figure fell short of the Zacks Consensus Estimate by 0.3% [2][10] Revenue Breakdown - U.S. rental revenues were $13.1 million, down 4.5% year-over-year, attributed to a less favorable reimbursement mix and a decrease in the number of patients on service [5] - Total sales revenues reached $68.6 million, up 3.4% from the prior year, with U.S. sales at $36.1 million (down 5.1%) and international sales at $32.5 million (up 14.8%) [6][10] Margin Analysis - Inogen's adjusted gross profit decreased by 3.3% year-over-year to $38 million, with the adjusted gross margin contracting by 260 basis points to 46.5% [7] Expense Management - Sales and marketing expenses decreased by 4.4% to $23.1 million, R&D expenses fell by 9.9% to $5.3 million, and general and administrative expenses decreased by 8.5% to $16.1 million [8] - Adjusted operating expenses totaled $41.4 million, down 5.2% year-over-year, with an adjusted operating loss of $6.2 million compared to $7.4 million in the prior year [8] Financial Position - At the end of Q4 2025, Inogen had cash and cash equivalents of $103.7 million, a slight decrease from $106.5 million at the end of Q3 2025 [9][11] - The company reported no debt on its balance sheet and cumulative net cash used in operating activities was $11.2 million [11] Future Guidance - For Q1 2026, Inogen expects revenues to align with Q1 2025, with the Zacks Consensus Estimate at $90.8 million [12] - For the full year 2026, the revenue outlook is between $366 million and $373 million, indicating approximately 6% growth at the midpoint compared to 2025 [12] Strategic Developments - Inogen expanded its product portfolio with the launch of new products aimed at the sleep therapy market and initiated a limited market release of a new airway clearance device [14][15] - The company also launched a new patient portal to enhance digital health capabilities and announced a strategic collaboration with Yuwell Medical to expand its product offerings in China [15]

Core Insights - Inogen reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.36, and an improvement from a loss of $0.41 per share a year ago [1] - The earnings surprise for the quarter was +27.78%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $81.72 million, slightly missing the Zacks Consensus Estimate by 0.34%, but showing an increase from $80.08 million year-over-year [3] Financial Performance - The company has shown a consistent ability to exceed consensus EPS estimates, achieving this four times in the last four quarters [2] - Inogen's stock has underperformed the market, losing about 15.5% since the beginning of the year, compared to a decline of 0.1% for the S&P 500 [4] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $90.8 million, and for the current fiscal year, it is -$0.51 on revenues of $391.5 million [8] - The Zacks Rank for Inogen is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [7] Industry Context - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9] - LivaNova, another company in the same industry, is expected to report quarterly earnings of $0.80 per share, reflecting a year-over-year change of -1.2%, with revenues projected at $350.93 million, up 9.1% from the previous year [10][11]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was approximately $82 million, with full-year revenue reaching nearly $349 million, reflecting a 4% year-over-year growth [5][20] - Adjusted EBITDA for 2025 was positive at $2.7 million, marking the first year of profitability since 2021 [9][25] - Net loss for the full year 2025 was $23 million, with adjusted net loss narrowing to $8 million, a 61% reduction from $20 million in 2024 [10][24] Business Line Data and Key Metrics Changes - U.S. sales for Q4 were $36.1 million, down 5.1% from $38 million in the prior year, while rental revenue was $32.5 million, up 14.8% from $28.3 million [20][21] - International business delivered $32.5 million in Q4 revenue, representing 15% year-over-year growth, driven by strong demand and successful international tenders [8][20] Market Data and Key Metrics Changes - Unit volumes grew more than 20% year-over-year in Q4, driven by demand for products and a shift from traditional oxygen tanks to portable oxygen concentrators (POCs) [6][7] - The global COPD market remains underpenetrated, with significant opportunities for growth as healthcare systems shift care into the home [9] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving top-line growth, advancing profitability, and expanding the innovation pipeline [5] - A $30 million share repurchase program was authorized, reflecting confidence in the company's strategy and commitment to enhancing shareholder value [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering improving performance in 2026, despite a shift in order timing due to customer budget constraints [6][10] - The company expects to achieve approximately 6% year-over-year revenue growth for 2026, with a focus on new product launches and strong demand for POCs [26][27] Other Important Information - The company has diversified its product portfolio to include oxygen therapy, sleep therapy, airway clearance, and digital health solutions, significantly expanding its addressable market from approximately $400 million to over $3 billion [18][30] - The company plans to launch at least one new product per year, focusing on higher-margin, clinically differentiated solutions [19][31] Q&A Session Summary Question: Impact of large customer orders shifting into 2026 - Management indicated that the shift was estimated to impact revenue by a couple hundred basis points, with orders expected to be spread throughout the first half of 2026 [36][39] Question: Performance of the direct-to-consumer channel in Q4 - The direct-to-consumer channel saw a decline of 15% in Q4, continuing to improve from previous quarters [40] Question: Revenue ramp from the Aurora mask launch - Management expects the Aurora mask launch to gain traction in Q2 and Q3, with a back-end loaded revenue contribution [44][45] Question: Growth expectations for Simeox in 2026 - Simeox generated $6 million in 2025, primarily from international markets, with expectations for continued growth supported by clinical trials and reimbursement submissions [52][54] Question: EBITDA guidance for 2026 - Management confirmed a commitment to positive Adjusted EBITDA for 2026, with expectations for quarterly performance to align with historical trends [55][58]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was approximately $82 million, with full-year revenue reaching nearly $349 million, reflecting a 4% year-over-year growth [5][20] - Adjusted EBITDA for 2025 was positive at $2.7 million, marking the first year of adjusted EBITDA profitability since 2021 [9][25] - Net loss for the full year 2025 was $23 million, with adjusted net loss narrowing to $8 million, a 61% reduction from $20 million in 2024 [10][24] Business Line Data and Key Metrics Changes - U.S. sales for Q4 were $36.1 million, down 5.1% from $38 million in the prior year, while rental revenue was $32.5 million, up 14.8% from $28.3 million [20][21] - International revenue for Q4 was $32.5 million, representing a 15% year-over-year growth, driven by strong demand and successful international tenders [8][20] - The company experienced over 20% year-over-year growth in unit volumes for both Q4 and the full year [6] Market Data and Key Metrics Changes - The global COPD market remains underpenetrated, with long-term oxygen therapy significantly underutilized in many regions, presenting substantial growth opportunities [9] - The U.S. market is seeing a shift where approximately 59% of new patients are starting with portable oxygen concentrators (POCs) instead of traditional oxygen tanks [38] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving top-line growth, advancing profitability, and expanding the innovation pipeline [5] - Inogen aims to launch at least one new product per year, with a commitment to higher margin, clinically differentiated solutions [19][31] - The company is transitioning from a single-product focus to a diversified respiratory care platform, expanding into areas such as sleep therapy and digital health solutions [18][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering improving performance in 2026, despite some order shifts from Q4 to Q1 due to customer budget constraints [6][29] - The company anticipates continued growth in the B2B channel, with mid-single-digit growth expected for both Q1 and the full year [38] - Management highlighted the importance of operational excellence and disciplined cost management in strengthening the financial foundation [9][10] Other Important Information - The company announced a $30 million share repurchase program, reflecting confidence in its strategy and commitment to enhancing shareholder value [11][62] - The estimated total addressable market (TAM) has expanded from approximately $400 million in POC concentrators to over $3 billion across the combined portfolio [18][30] Q&A Session Summary Question: Impact of large customer orders shifting into 2026 - Management indicated that the shift was estimated to impact revenue by a couple hundred basis points, with orders expected to materialize throughout the first half of 2026 [36][39] Question: Performance of the direct-to-consumer (DTC) channel - The DTC channel showed improvement, with a decline of 15% in Q4, continuing the trend of reduced negative growth [40] Question: Revenue ramp from the Aurora mask launch - Management expects the Aurora mask revenue to be back-end loaded in 2026, with traction anticipated in Q2 and Q3, which are typically stronger quarters [44][45] Question: Growth expectations for Simeox in 2026 - Simeox generated $6 million in 2025, primarily from international markets, with expectations for continued growth supported by clinical trials and reimbursement submissions [52][54] Question: EBITDA guidance for 2026 - Management confirmed a commitment to improving adjusted EBITDA, with expectations for positive adjusted EBITDA throughout 2026, though investments in R&D may impact quarterly results [55][57]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was approximately $82 million, with full-year revenue reaching nearly $349 million, reflecting a 4% year-over-year growth [5][20] - Adjusted EBITDA for 2025 was positive at $2.7 million, marking the first year of adjusted EBITDA profitability since 2021 [9][25] - The net loss for the full year 2025 was $23 million, with an adjusted net loss narrowing to $8 million, a 61% reduction from $20 million in 2024 [10][24] Business Line Data and Key Metrics Changes - U.S. sales for Q4 were $36.1 million, down 5.1% from $38 million in the prior year, while international revenue was $32.5 million, representing 15% year-over-year growth [20][8] - The rental business saw revenue of $32.5 million in Q4, up 14.8% from $28.3 million in the prior period, driven by higher demand and successful geographic expansion [21][22] - Unit volumes grew more than 20% year-over-year in Q4, driven by demand for products and the shift from traditional oxygen tanks to portable oxygen concentrators (POCs) [6] Market Data and Key Metrics Changes - The international business delivered $32.5 million in Q4 revenue, indicating a strong growth trajectory and reinforcing the company's position as a trusted global partner in oxygen therapy [8] - The global COPD market remains underpenetrated, with long-term oxygen therapy significantly underutilized in many regions, presenting substantial growth opportunities [9] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving top-line growth, advancing profitability, and expanding the innovation pipeline [5] - A $30 million share repurchase program was authorized, reflecting confidence in the company's strategy and commitment to enhancing shareholder value [11] - The company aims to launch at least one new product per year, with a focus on higher-margin, clinically differentiated solutions [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering improving performance in 2026 and beyond, despite a shift in order timing due to customer capital constraints [6][28] - The company expects to achieve approximately 6% year-over-year revenue growth for 2026, driven by new product launches and strong demand for POCs [26] - Management highlighted the transformation from a single-product company to a diversified respiratory care platform, with a significant expansion in the total addressable market from approximately $400 million to over $3 billion [18][29] Other Important Information - The company ended 2025 with $120.9 million in cash equivalents and no debt, providing financial flexibility for growth investments [10][25] - The introduction of new products, including the Voxi 5 stationary oxygen concentrator and Aurora CPAP masks, is expected to drive future growth [16][17] Q&A Session Summary Question: Impact of large customer orders shifting into 2026 - Management indicated that the shift was estimated to impact revenue by a couple hundred basis points, with orders expected to spread throughout the first half of 2026 [34][35] Question: Performance of the direct-to-consumer (DTC) channel in Q4 - The DTC channel was down 15% in Q4, continuing to improve from previous quarters, reflecting a tough comparison due to prior year rebasing [39][40] Question: Revenue ramp from the Aurora mask launch - Management expects the Aurora mask revenue to be back-end loaded in 2026, with strong traction anticipated in Q2 and Q3 [42][44] Question: Growth expectations for Simeox in 2026 - Simeox generated $6 million in 2025, primarily from international markets, with expectations for continued growth supported by clinical trials and reimbursement submissions [51][54] Question: EBITDA guidance for 2026 - Management confirmed a commitment to improving adjusted EBITDA, with expectations for positive adjusted EBITDA throughout 2026, though investments in R&D may impact quarterly results [55][57]

February 24, 2026 Q4 2025 Supplemental Financial Information Use of Non-GAAP Financial Measures Inogen has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three and twelve months ended December 31, 2025, and December 31, 2024, and for the fiscal year ended December 31, 2023. Management believes that these non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors b ...

Core Viewpoint - Inogen (INGN) shares experienced a significant increase of 6.6% to close at $6.13, driven by strong trading volume and a positive preliminary revenue update indicating steady growth and improved profitability [1][2]. Financial Performance - Inogen reported estimated fourth-quarter 2025 revenue of approximately $82 million, reflecting a year-over-year increase of about 2% [2][3]. - The full-year revenue for 2025 is projected to be around $349 million, indicating an annual growth rate of 4% [2]. - The company is expected to report a quarterly loss of $0.36 per share, which represents a year-over-year change of +12.2% [3]. Profitability and Operational Efficiency - Management indicated that Inogen is on track to achieve positive adjusted EBITDA for the full year of 2025, highlighting improvements in operating leverage, cost controls, and financial discipline [2]. Market Sentiment and Stock Performance - Despite the recent rise in stock price, the consensus EPS estimate for the upcoming quarter has been revised 5.3% lower over the last 30 days, which may indicate potential challenges ahead [5]. - The stock currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks in the same industry [6]. Industry Comparison - Inogen operates within the Zacks Medical - Instruments industry, where another company, Lucid Diagnostics Inc. (LUCD), saw a slight decline of 0.8% in its last trading session [6]. - Lucid Diagnostics has a consensus EPS estimate of -$0.07 for its upcoming report, reflecting a year-over-year change of +63.2% [7].